A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men
with high-risk non-metastatic castration-resistant prostate cancer.